Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday.

In morning trade, the ASX All Ords stock is up 7% to $1.51.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX All Ords stock jumping today?

Investors have been buying the regenerative medicine company's shares following the release of an announcement relating to its flagship Remplir product.

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.

It was recently given the thumbs up by the US Food & Drug Administration, paving the way for the company to start generating revenue in the country.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.

What is today's news?

According to the release, the company has added a further eight distributors for Remplir, taking the total number of US distributors signed to 12.

Management notes that the signing of distributors has progressed well ahead of expectations with the company previously only targeting 10 distributors in place by 30 June. It feels that the rapid signing of these new distributors is a testament to the quality of Remplir and the distributors' belief in being able to generate strong sales for the product in the US.

Following these new appointments, the ASX All Ords stock's distributor group collectively covers 21 US states. And with these relationships non-exclusive, the company intends to continue signing additional distributors to expand access to the US market.

'Confident'

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

It's very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We're well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.

Our US team has been working tirelessly leading up to the product launch and we're confident we have the right strategy to drive market penetration of the US. For us, that means a combination of experienced internal employees complemented by a portfolio of distributors who have active sales channels to reach and engage our customers. We expect to grow our portfolio of distributors too.

Following today's strong gain, this ASX All Ords stock is now up almost 300% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Ecstatic woman looking at her phone outside with her fist pumped.
Healthcare Shares

Why is this ASX 300 stock rocketing 17% today?

Let's see what is getting investors excited today.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Should you buy CSL and Pro Medicus shares today?

Both stocks have been hammered, but brokers see upside of 60% or more.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech company has piled on more than 25% after a big announcement

A deal around a novel drug delivery compound has investors interested.

Read more »

A young man stands facing the camera and scratching his head with the other hand held upwards wondering if he should buy Whitehaven Coal shares
Healthcare Shares

Telix shares drop despite promising US FDA update

Market weakness is overshadowing this news.

Read more »

Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this ASX share deliver healthy returns or will things get worse?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »

Woman with a concerned look on her face holding a credit card and smartphone.
Healthcare Shares

What on earth's going on with the CSL share price?

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more…

Read more »